Literature DB >> 32971009

Evaluation of the COVID-19 response in Spain: principles and requirements.

Alberto L García-Basteiro1, Helena Legido-Quigley2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32971009      PMCID: PMC7505572          DOI: 10.1016/S2468-2667(20)30208-5

Source DB:  PubMed          Journal:  Lancet Public Health


× No keyword cloud information.
A resurgence of COVID-19 infections is occurring in Spain, with some of the worst figures in Europe.1, 2 In August, 2020, we urged the Spanish Central Government and regional governments to independently evaluate their COVID-19 response to identify areas where public health and the health and social care system need to be improved. Although we received widespread support from more than 50 scientific societies and associations representing public health, medical, and nursing professional communities; there is now a need to define such an evaluation in terms of its timing, scope, and leadership. Here, we suggest three major requisites and four guiding principles, adapted from McKee and colleagues, which we believe would ensure a successful independent evaluation. The first requirement is urgency; the evaluation should start immediately and report periodically until the end of the pandemic. In a country where political tensions are high, the second requirement is widescale support from political parties, scientific associations, health-care professionals, patients and carers, civil society, and the society as a whole. The reaction to our first letter was positive among all stakeholders, and governments should capitalise on that consensus. The third requirement is a firm commitment from the Central Government and regional governments to listen to the recommendations proposed in the evaluation and act accordingly. Once the requirements have been agreed, we suggest four guiding principles to guarantee a successful process. The first, and most important, principle is the independence of the members of the evaluation committee. The people who select the members of the evaluation team, and the members themselves, should be independent from government, not have worked in government, and have no competing interests. Independent Spanish academics, working both in Spain and abroad, and international experts could take part in the selection committee and the evaluation team. Second, a no-blame culture is needed, focusing on providing recommendations that can improve the situation without apportioning blame. Third, the evaluation team should be gender balanced and multidisciplinary to promote broader critical evaluation. Fourth, the evaluation should have a broad scope, analysing the health, economic, and social effects with input from both the Central Government and the autonomous communities, given the high level of decentralised competencies. The organisation of the evaluation can be chosen from existing models, such as the evaluation proposed by WHO, the All-Party Parliamentary Group model used in the UK, or the inquiry that was done in Victoria state, Australia. One proposal could be to select a panel of experts supported by a scientific team who are responsible for collecting and analysing the evidence. Working groups and a call for evidence could also complement that process, involving relevant scientific societies representing health-care and other professionals, patients' organisations, and civil society in the provision of evidence and expertise. We continue to encourage the Spanish Central Government and regional governments to take forward this evaluation, which could become an example for other countries to replicate. We will continue to offer more detailed proposals. This evaluation, based on scientific evidence, is now urgently needed to guide public health policy and contribute to overcoming the COVID-19 pandemic.
  9 in total

1.  [Translated article] COVID-19 in Youth and the Fifth Wave.

Authors:  Joan B Soriano; José Ramón Villagrasa; Julio Ancochea
Journal:  Arch Bronconeumol       Date:  2022-02-18       Impact factor: 4.872

2.  [COVID-19 in Youth and the Fifth Wave].

Authors:  Joan B Soriano; José Ramón Villagrasa; Julio Ancochea
Journal:  Arch Bronconeumol       Date:  2021-09-14       Impact factor: 6.333

3.  The Management of the COVID-19 Pandemic Evidences the Need to Transform Spain's Public Health Education.

Authors:  Miguel Angel Luque-Fernandez; Aurelio Tobias
Journal:  Int J Public Health       Date:  2022-04-28       Impact factor: 5.100

4.  A pandemic that needs assessment.

Authors:  Joan Carles March
Journal:  J Healthc Qual Res       Date:  2020 Nov - Dec

5.  [Insight on how to assess and improve the response to the COVID-19 pandemic].

Authors:  José M Martín-Moreno; Alex Arenas; Rafael Bengoa; Carme Borrell; Manuel Franco; Alberto L García-Basteiro; Juan Gestal; Beatriz González López-Valcárcel; Ildefonso Hernández Aguado; Helena Legido-Quigley; Joan Carles March; Sergio Minué; Carles Muntaner; Carmen Vives-Cases
Journal:  Gac Sanit       Date:  2020-12-17       Impact factor: 2.139

6.  Internal dynamics within primary care teams in two Spanish regions during the COVID-19 pandemic: a qualitative study.

Authors:  Montserrat Pulido-Fuentes; Ana María Palmar-Santos; Juan Antonio Flores-Martos; Carmen Cipriano-Crespo; Laura Alicia Rubio; Luisa Abad González; MVictoria Navarta-Sánchez
Journal:  BMC Prim Care       Date:  2022-03-31

7.  Impact of COVID-19 lockdown on diabetes management and follow-up in a broad population in Spain.

Authors:  Ana Palanca; Carmen Quinones-Torrelo; Juan Girbés; José T Real; F Javier Ampudia-Blasco
Journal:  Eur J Clin Invest       Date:  2022-03-27       Impact factor: 5.722

Review 8.  Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.

Authors:  Engy Elekhnawy; Walaa A Negm; Suzy A El-Sherbeni; Ahmed Zayed
Journal:  Inflammopharmacology       Date:  2022-08-26       Impact factor: 5.093

9.  Lessons Learned from Japan's Response to the First Wave of COVID-19: A Content Analysis.

Authors:  Kazuki Shimizu; Masashi Negita
Journal:  Healthcare (Basel)       Date:  2020-10-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.